Jiangsu Recbio Technology Co., Ltd.
2179.HK
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.34B
Close$
$-2.36
153.6% downside
Current Fair Value
153.6% downsideOvervalued by 153.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.34 Billion |
|---|---|
| Enterprise Value | $2.84 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.12 |
| Beta | 0.08 |
| Outstanding Shares | 615,858,702 |
Return
| Return on Equity | -227.11% |
|---|---|
| Return on Assets | -70.86% |
| Return on Invested Capital | -134.23% |
Valuation & Multiples
| P/E Ratio | -4.88 |
|---|---|
| PEG | 12.91 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 73.97 |
| Enterprise Value to EBIT | -2.55 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.24 |
| Debt to Equity | 1.38 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
$11.93 M
Average shareholder expectationNext Earnings Call
Expected Date
April 1, 2027
EPS Estimate
$-0.78
Average shareholder expectationRevenue Estimate
$11.93 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jiangsu Recbio Technology Co., Ltd.
491 employees
CEO: Yong Liu Jiangsu Recbio Technology Co., Ltd. operates as a biotechnology company primarily engaged in the pioneering research, development, and eventual market introduction of subunit vaccines throughout the People's Republic of China. A signific...